| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $7,792,358 | 10 | 100 |
| GOLDSTEIN DOV A MD | Chief Financial Officer | 0 | $0 | 1 | $531,828 | $-531,828 |
| RUBIN PAUL D | Chief Medical Officer | 0 | $0 | 6 | $1.46M | $-1.46M |
| Barton Shane | Principal Accounting Officer | 0 | $0 | 2 | $1.58M | $-1.58M |
| Fortney Kristen | Chief Executive Officer | 0 | $0 | 1 | $4.22M | $-4.22M |
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular …
Over the last 12 months, insiders at BioAge Labs Inc. have bought $0 and sold $7.79M worth of BioAge Labs Inc. stock.
On average, over the past 5 years, insiders at BioAge Labs Inc. have bought $101,376 and sold $7.79M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,000 shares for transaction amount of $54,000 was made by Hemrajani Rekha (director) on 2024‑09‑27.
| 2026-06-30 | Sale | Barton Shane | Principal Accounting Officer | 20,216 0.0552% | $25.19 | $509,176 | -61.28% | |
| 2026-06-29 | Sale | Barton Shane | Principal Accounting Officer | 42,350 0.1136% | $25.21 | $1.07M | -61.92% | |
| 2026-04-01 | Sale | RUBIN PAUL D | Chief Medical Officer | 8,820 0.0246% | $17.81 | $157,084 | -8.69% | |
| 2026-03-02 | Sale | RUBIN PAUL D | Chief Medical Officer | 7,433 0.0189% | $20.30 | $150,890 | -23.68% | |
| 2026-02-02 | Sale | RUBIN PAUL D | Chief Medical Officer | 7,433 0.0193% | $18.75 | $139,369 | -15.52% | |
| 2026-01-13 | Sale | Fortney Kristen | Chief Executive Officer | 233,107 0.5693% | $18.12 | $4.22M | -16.43% | |
| 2026-01-13 | Sale | GOLDSTEIN DOV A MD | Chief Financial Officer | 27,000 0.0717% | $19.70 | $531,828 | -16.43% | |
| 2026-01-02 | Sale | RUBIN PAUL D | Chief Medical Officer | 7,433 – | $12.85 | $95,490 | +34.22% | |
| 2025-12-09 | Sale | RUBIN PAUL D | Chief Medical Officer | 18,000 0.0403% | $12.00 | $216,000 | +39.76% | |
| 2025-12-04 | Sale | RUBIN PAUL D | Chief Medical Officer | 68,897 0.1308% | $10.19 | $701,909 | +59.90% | |
| 2024-09-27 | Hemrajani Rekha | director | 3,000 0.0101% | $18.00 | $54,000 | -78.38% | ||
| 2024-09-27 | Barton Shane | Principal Accounting Officer | 2,632 0.0088% | $18.00 | $47,376 | -78.38% | ||
| 2017-08-15 | BRINER KURT W | director | 133,333 0.0186% | $0.75 | $100,000 | |||
| 2017-08-15 | Settino Mario | Chief Financial Officer | 20,000 0.0028% | $0.75 | $15,000 | |||
| 2017-08-15 | LAND RAYMOND J | director | 53,333 0.0075% | $0.75 | $40,000 | |||
| 2017-08-15 | Haller Heinz | director | 40,000 0.0056% | $0.75 | $30,000 | |||
| 2017-08-15 | Orecchioni Fabrice | Chief Operations Officer | 26,666 0.0037% | $0.75 | $20,000 | |||
| 2017-08-15 | Millis James | Chief Technology Officer | 13,333 0.0019% | $0.75 | $10,000 | |||
| 2017-08-15 | RICHSTONE ELLEN B | director | 13,333 0.0019% | $0.75 | $10,000 | |||
| 2017-08-09 | Settino Mario | Chief Financial Officer | 15,000 0.0015% | $0.53 | $8,024 |
| Increased Positions | 67 | +78.82% | 7M | +33.08% |
| Decreased Positions | 32 | -37.65% | 5M | -22.48% |
| New Positions | 27 | New | 5M | New |
| Sold Out Positions | 9 | Sold Out | 2M | Sold Out |
| Total Postitions | 120 | +41.18% | 24M | +10.6% |